PeptideSearch

Ipamorelin

Very early research

Get notified when the evidence changes.

The research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-06-12

Also called NNC 26-0161 / Growth hormone secretagogue

A lab-made peptide studied for raising the body's own growth hormone. Research stalled early and there is no approved use.

The basics

What is it?
A lab-made peptide that nudges the body to release its own growth hormone.
What do we know?
In early tests it does raise growth hormone in the blood, without much effect on other hormones.
What do we still not know?
Whether raising growth hormone this way changes anything people care about. Development was dropped years ago.

Official status: Not nominated for 503A compounding · Checked 2026-06-12

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Category 2 — FDA flagged a safety concern

Not FDA approved and not on the 503A bulks list, so there is no legal compounding pathway.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 16

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 21 March 2025503B

    FDA lists "Ipamorelin Acetate" — the acetate salt, the form pharmacies handle — under 503B Category 2: Bulk Drug Substances that Raise Significant Safety Risks. Outsourcing facilities are not to compound it. Read from the FDA 503B category document dated March 21, 2025.

    FDA

We'll email you when a new study, trial or status change lands for Ipamorelin. Unsubscribe in one click.